+

PE20081803A1 - Sintesis y caracterizacion de la forma ii polimorfica de 4-(2-(4,4-dimetil-2-oxooxazolidin-3-il)tiazol-4-il)benzonitrilo - Google Patents

Sintesis y caracterizacion de la forma ii polimorfica de 4-(2-(4,4-dimetil-2-oxooxazolidin-3-il)tiazol-4-il)benzonitrilo

Info

Publication number
PE20081803A1
PE20081803A1 PE2008000431A PE2008000431A PE20081803A1 PE 20081803 A1 PE20081803 A1 PE 20081803A1 PE 2008000431 A PE2008000431 A PE 2008000431A PE 2008000431 A PE2008000431 A PE 2008000431A PE 20081803 A1 PE20081803 A1 PE 20081803A1
Authority
PE
Peru
Prior art keywords
oxooxazolidin
thiazol
benzonitrile
dimethyl
characterization
Prior art date
Application number
PE2008000431A
Other languages
English (en)
Inventor
Mahmoud Mirmehrabi
Yuping Niu
Abdolsamdad Tadayon
Subodh Deshmukh
M Sherry Ku
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PE20081803A1 publication Critical patent/PE20081803A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A UNA FORMA CRISTALINA DEL COMPUESTO 4-(2-(4,4-DIMETIL-2-OXOOXAZOLIDIN-3-IL)TIAZOL-4-IL)BENZONITRILO QUE TIENE UN PATRON DE DIFRACCION DE RAYOS X QUE COMPRENDE PICOS EXPRESADOS EN ANGULOS DE 2O DE 8.67, 9.70, 12.29, 13.10, 17.37, 17.92, 23.39, 25.81 Y 26.12. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION DE LA FORMA CRISTALINA Y A UNA COMPOSICION FARMACEUTICA. DICHO COMPUESTO ES UN MODULADOR DEL RECEPTOR DE PROGESTERONA SIENDO UTIL EN EL TRATAMIENTO DE FIBROIDES, LEIOMIOMATA UTERINA, ENDOMETRIOSIS, SANGRADO DISFUNCIONAL, CARCINOMAS DEPENDIENTES DE HORMONAS
PE2008000431A 2007-03-09 2008-03-05 Sintesis y caracterizacion de la forma ii polimorfica de 4-(2-(4,4-dimetil-2-oxooxazolidin-3-il)tiazol-4-il)benzonitrilo PE20081803A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US90609407P 2007-03-09 2007-03-09

Publications (1)

Publication Number Publication Date
PE20081803A1 true PE20081803A1 (es) 2008-12-11

Family

ID=39385825

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000431A PE20081803A1 (es) 2007-03-09 2008-03-05 Sintesis y caracterizacion de la forma ii polimorfica de 4-(2-(4,4-dimetil-2-oxooxazolidin-3-il)tiazol-4-il)benzonitrilo

Country Status (7)

Country Link
US (1) US20080234340A1 (es)
AR (1) AR065635A1 (es)
CL (1) CL2008000663A1 (es)
PA (1) PA8771701A1 (es)
PE (1) PE20081803A1 (es)
TW (1) TW200902525A (es)
WO (1) WO2008112498A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016003917A1 (en) 2014-07-03 2016-01-07 Quanticel Pharmaceuticals, Inc. Inhibitors of lysine specific demethylase-1

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005302708A1 (en) * 2004-10-27 2006-05-11 Janssen Pharmaceutica N.V. Trisubstituted thiophenes as progesterone receptor modulators
CA2585544A1 (en) * 2004-10-27 2006-05-11 Janssen Pharmaceutica N.V. Pyridine imidazoles and aza-indoles as progesterone receptor modulators
WO2006111856A1 (en) * 2005-04-20 2006-10-26 Pfizer Limited Pyrazole derivatives as progesterone receptor antagonists
TW200815428A (en) * 2006-08-15 2008-04-01 Wyeth Corp Oxazolidone derivatives as PR modulators
WO2008112495A1 (en) * 2007-03-09 2008-09-18 Wyeth Synthesis and characterization of polymorph form iii of 4-(2,(4,4-dimethyl-2-oxooxazolidin-3-yl)thiazol-4-yl)benzonitrile

Also Published As

Publication number Publication date
WO2008112498A3 (en) 2008-11-06
TW200902525A (en) 2009-01-16
PA8771701A1 (es) 2008-11-19
WO2008112498A2 (en) 2008-09-18
AR065635A1 (es) 2009-06-17
US20080234340A1 (en) 2008-09-25
CL2008000663A1 (es) 2008-05-30

Similar Documents

Publication Publication Date Title
DOP2015000276A (es) Derivados de 17–hidroxi–17–pentafluoroetil–estra–4,9(10)–dien–11–arilo con accion antagonista en el receptor de progesterona
CL2007003266A1 (es) Compuestos derivados de progesterona, antagonistas del receptor de progesterona; composicion farmaceutica; y uso para el tratamiento de endometriosis, miomas o tumores dependientes de hormonas.
WO2007016385A3 (en) Use of substituted 5-amino-1h-pyrrole-2-carbonitrile derivatives as progesterone receptor modulators
GT200600155A (es) Compuestos utiles en terapia
WO2011098437A3 (de) Progesteronrezeptorantagonisten
BR112014021331A8 (pt) Antagonistas do receptor do hormônio liberador de gonadotropina, composição farmacêutica compreendendo os mesmos e uso desses
PE20061322A1 (es) Forma purificada de tanaproget
PE20081803A1 (es) Sintesis y caracterizacion de la forma ii polimorfica de 4-(2-(4,4-dimetil-2-oxooxazolidin-3-il)tiazol-4-il)benzonitrilo
PE20070182A1 (es) Derivados cianopirrol-fenil amida como moduladores del receptor de progesterona
AR065521A1 (es) Heterociclos sulfonilados utiles para la modulacion del receptor de progesterona
TW200738665A (en) Nonsteroidal progesterone receptor modulators
DE602005019905D1 (de) -modulatoren
EA201100226A1 (ru) Производные эстратриена, содержащие гетероциклические биоизостеры для фенольного а-кольца
MX2015014264A (es) Forma de dosificacion de un antagonista del receptor de progesterona.
EA200702524A1 (ru) Нестероидные модуляторы рецептора прогестерона
WO2008109055A8 (en) Cyanopyrrole sulfonamides useful for modulation of the progesterone receptor
PA8772001A1 (es) "SÍNTESIS Y CARACTERIZACIÓN DE LLA FORMA III POLIMÓRFICA DE 4-(-2-(4,4-DIMETIL-2-OXOOXAZOLIDIN-3i)BENZONITRILO"
CN116096371A (zh) 含有饱和含氧杂环基的嘧啶二酮类化合物及其用途
DK1809602T3 (da) Indolderivater, der kan anvendes som progesteronreceptormodulatorer
AR073007A1 (es) Derivados de oxazol utiles para tratar trastornos mediados por el receptor mglur5
RU2009123421A (ru) Способ применения наноформы транс-резвератрола для лечения и профилактики гормонозависимых пролиферативных процессов, в том числе опухолей
CL2007003723A1 (es) Compuestos ciclicos o heterociclicos sustituidos, moduladores no esteroidales del receptor de progesterona; composicion farmaceutica; y uso para tratar y/o prevenir enfermedades ginecologicas tal como endometriosis y dismenorrea, tumores dependientes
BR112017023894A2 (pt) derivados de etinila

Legal Events

Date Code Title Description
FX Voluntary withdrawal
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载